Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
Maria, Durvanei Augusto; Will, Sonia Elisabete Alves de Lima; Bosch, Rosemary Viola; Souza, Jean Gabriel de; Sciani, Juliana Mozer; Goldfeder, Mauricio Barbugiani; Rondon, Giuliana Gaggini; Chudzinski-Tavassi, Ana Marisa.
Toxicol. Rep.
; 6: p. 51-63, 2019.
Artículo
Inglés
| SES-SP, SES SP - Instituto Butantan, SES-SP | ID: but-ib15745
Amblyomin-X, a Kunitz-type protease inhibitor, is a recombinant protein that selectively induces apoptosis in tumor cells and promotes tumor reduction in vivo in melanoma animal models. Furthermore, Amblyomin-X was able to drastically reduce lung metastasis in a mice orthotopic kidney tumor model. Due to its antitumor activity, Amblyomin-X potential to become a new drug is currently under investigation, therefore the aim of the present study was to perform preclinical assays to evaluate Amblyomin-X toxicity in healthy mice. Exploratory toxicity assays have shown that treatment with 512?mg/kg of Amblyomin-X lead to animal mortality, therefore two groups of treatment were evaluated in the present work in the acute toxicity assay, animals were injected once with doses ranging from 4 to 256?mg/kg of Amblyomin-X, while in the subacute toxicity assay, animals were injected with 0.25, 0.57 and 1?mg/kg of Amblyomin-X daily, during 28 days. Following this treatment regimens, Amblyomin-X did not cause any mortality; moreover, toxicity signs were discrete, reversible and observed only at the higher doses, thus establishing a safety profile for administration in mice, which can be further used to determine the dose translation of this novel drug candidate for treatment in other species.
Biblioteca responsable:
BR78.1
Ubicación: BR78.1
Texto completo
Documentos relacionados
